Available Trials

---

• Breast
• Cholangiocarcinoma
• Colorectal/GI/Gastrointestinal
• Endometrial
• Fallopian Tube
• Gastric
• Gynecological/Ovarian
• Head/Neck
• Leukemia
• Lung - Non-Small Cell Lung
• Lung - Small Cell Lung
• Lymphoma
• Peritoneal Cancer
• Prostate
• Solid Tumor
• STAR: Selected Trials Available for Accelerated Four Week Rollout
• Urothelial

---

Breast

• USOR 23309 - Ph3 Study of Post-Neoadjuvant MK2870 in combo with Pembro (MK3475) with triple neg breast cancer

  A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 24151 - Ph3 study of standard endocrine therapy with breast cancer

  Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

---

Cholangiocarcinoma

• USOR 23066 - STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

  TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
  

  Available at Arlington Heights, Niles, Chicago Resurrection

---

Colorectal/GI/Gastrointestinal

• USOR 24093 - Ph3 study of T-DXd vs SOC gemcitabine for HER2-expressing Biliary Tract Cancer

  DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (D781PC00001)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

---

Endometrial

• USOR 24046 - Ph3 study of T-DXd in patients with HER2-expressing endometrial cancer

  An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as FirstLine Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
  

  Available at Arlington Heights, Chicago Resurrection, Niles

---

Fallopian Tube

• USOR 21270 - Ph2 ZN-c3 Tumor DNA Repair CCGA

  A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  

  Available at Arlington Heights, Niles

---

Gastric

• USOR 24152 - Ph3 study of ARTEMIDE-GASTRIC01 in combo with pembro FIL gastric cancer

  A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First line Treatment of HER2-positive Gastric Cancer.
  

  Available at Arlington Heights, Chicago Resurrection, Niles

---

Gynecological/Ovarian

• USOR 21270 - Ph2 ZN-c3 Tumor DNA Repair CCGA

  A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  

  Available at Arlington Heights, Niles

---

Head/Neck

• USOR 23234 - Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)

  A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC), D798EC00001
  

  Available at Arlington Heights, Niles

• USOR 24004 - STAR Ph3 study to evaluate to treat patients with HNSCC

  A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
  

  Available at Arlington Heights, Niles

---

Leukemia

• USOR 24266 - Ph3 Study of Sonrotoclax plus Anti-CD20 in patients with chronic/small Lymphocytic Leukemia/Lymph

  A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  

  Available at Arlington Heights, Niles

---

Lung - Non-Small Cell Lung

• USOR 25091 - ACCELERO: Ph3 Study to evaluate PF-08046054 vs Docetaxel in PD-L1+ NSCLC

  A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 24189 - Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)

  A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  

  Available at Arlington Heights, Niles

• USOR 22118 - Ph3 Soto/Doublet vs Pembro/Doublet NSCLC PD-L1 neg KRAS PG12C+ (CodeBreaK 202)

  A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) (20190341)
  

  Available at Arlington Heights, Niles

• USOR 23235 - Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

  A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)
  

  Available at Arlington Heights, Niles

• USOR 21541 - Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%

  A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
  

  Available at Arlington Heights, Niles

• USOR 20270 - Ph2 MRTX849 Pembro NSCLC KRAS

  A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. (849-007) (Mirati Therapeutics)
  

  Available at Arlington Heights, Niles

---

Lung - Small Cell Lung

• USOR 24188 - Ph3 multisite randomized trial of BNT327 in combo with participants with SCLC

  A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 24312 - Randomized study of BMS-986489 vs durvalumab in limited stage SCLC (TIGOS-LS)

  An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 23243 - Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237)

  A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)
  

  Available at Arlington Heights, Niles

---

Lymphoma

• USOR 24321 - Ph3 study to compare the combo in Golca+R with follicular lymphoma

  A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 24266 - Ph3 Study of Sonrotoclax plus Anti-CD20 in patients with chronic/small Lymphocytic Leukemia/Lymph

  A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  

  Available at Arlington Heights, Niles

• USOR 19062 - Ph 1b/3 Taze w/ R2 R/R Fol Lymph

  A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma (EZH-302)
  

  Available at Arlington Heights, Niles

---

Peritoneal Cancer

• USOR 21270 - Ph2 ZN-c3 Tumor DNA Repair CCGA

  A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  

  Available at Arlington Heights, Niles

---

Prostate

• USOR 24310 - Ph1/1b single agent in combo with an androgen receptor in patients with prostate

  An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer
  

  Available at Arlington Heights, Chicago Resurrection, Niles

---

Solid Tumor

• USOR 23253 - STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

  Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 23328 - STAR Ph2 study of BI 1810631 for the treatment of HER-2 mutated solid tumors

  Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours (1479-0009)
  

  Available at Arlington Heights, Niles

• USOR 22037 - STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

  A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
  

  Available at Arlington Heights, Niles

---

STAR: Selected Trials Available for Accelerated Four Week Rollout

• USOR 24305 - STAR: Ph3 study to evaluate the efficacy of firmonertinib with FIL treatment in patients with NSCLC

  A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 24320 - STAR: Ph3 multicenter study of taletrectinib in patients with ROS1-FUSION with NSCLC

  A PHASE 3 MULTICENTER DOUBLE-BLIND RANDOMIZED STUDY OF TALETRECTINIB VERSUS PLACEBO IN PATIENTS WITH ROS1-FUSION POSITIVE STAGE IB-IIIA NON-SMALL CELL LUNG CANCER WHO HAVE UNDERGONE COMPLETE TUMOR RESECTION
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 25010 - STAR Ph4 study of Ocular in patients with Tivdak in cervical cancer (GOG-3116)

  A Prospective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in Patients Treated with Tivdak in Recurrent or Metastatic Cervical Cancer
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 23107 - STAR Ph3 Study of OP-1250 Monotherapy vs SOC for ER+ HER2 mBreast CDK4/6 (OPERA-01)

  A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 inhibitor Therapy
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 23251 - STAR Ph3 AZD5305 with HR+ HER2 negative advanced breast cancer (EvoPAR-Breast01)

  A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 23253 - STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

  Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)
  

  Available at Arlington Heights, Chicago Resurrection, Niles

• USOR 23066 - STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

  TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
  

  Available at Arlington Heights, Niles, Chicago Resurrection

• USOR 22037 - STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

  A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
  

  Available at Arlington Heights, Niles

• USOR 24004 - STAR Ph3 study to evaluate to treat patients with HNSCC

  A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
  

  Available at Arlington Heights, Niles

---

Urothelial

• USOR 24257 - Ph3 study of (Dato-Dxd) in subjects with met. Urothelial Carcinoma

  A Randomized Open-Label Phase 2/3 Study of Datopotamab-Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed during or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment
  

  Available at Arlington Heights, Chicago Resurrection, Niles